Abstract C071: Association of sacituzumab govitecan treatment’s side effects and survival outcomes with age and race among triple negative breast cancer patients

Abstract Background: Sacituzumab govitecan (SG), an antibody-drug conjugate (ADC), showed promise as a second-line treatment option for triple negative breast cancer (TNBC). Our study aims to analyze the outcomes of SG by comparing differences in side effects and overall survival among older age and racial groups of TNBC patients after SG treatment. Methods: In this retrospective cohort study, a global network of adult patients from the TriNetX database with triple negative breast cancer and history of SG treatment were included. They were divided into cohorts based on age (<65 and >65 years) and race (non-Hispanic White and Black/African American). Occurrence of adverse events, including neutropenia, anemia, diarrhea, nausea and vomiting, and malaise and fatigue, were measured for up to 6 months after the index event or SG treatment. Overall survival was also noted up to 5 years after index event using Kaplan Meier analysis. The study was IRB exempt. Results: A total of 692 patients met inclusion criteria, with 500 patients of age <65 years and 192 >65 years, and 390 non-Hispanic White and 102 non-Hispanic Black patients. In terms of age, no differences were seen for adverse events between patients >65 or <65 years of age with neutropenia (OR: 1.00), anemia (OR: 1.16, 95% CI: 0.61-2.18), diarrhea (OR: 1.19, 95% CI: 0.67-2.1), nausea and vomiting (OR: 0.66, 95% CI: 0.35-1.24), malaise and fatigue (OR: 0.87, 95% CI: 0.47-1.6), cognitive function (OR: 0.75, 95% CI: 0.36-1.36), as well as 5-year survival (HR: 0.86, 95% CI: 0.67-1.09). Additionally, comparing White and Black patients, no differences were seen with neutropenia (OR: 1.09, 95% CI: 0.61-1.98), diarrhea (OR: 0.99, 95% CI: 0.5-1.98), nausea and vomiting (OR: 1.02, 95% CI: 0.49-2.11), and survival (HR: 1.05, 95% CI: 0.78-1.40). Conclusions: There is no difference in side effects and overall survival among patients age of >65 years compared to <65 years, as well as non-Hispanic Black compared to White TNBC patients after SG treatment. SG overall seems to be safe to use in older or black patient populations. Citation Format: Winni Gao, Regan Cronk, Navesh Sharma, Michelle J. Shriner, Rahul Kashyap. Association of sacituzumab govitecan treatment’s side effects and survival outcomes with age and race among triple negative breast cancer patients [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C071.